Report from the extraordinary general meeting in Orexo AB, 13 July 2012

The extraordinary general meeting resolved on 13 July to authorize the Board of
Directors to repurchase and transfer the company´s own shares. The meeting also
resolved on transfer of own shares under the Performance-based, Long-term
Incentive Program 2011/2021, to adopt a board member share plan 2012/2017, to
issue warrants to subscribe for new shares and to approve transfer of the
warrants or own shares under the board member share plan 2012/2017. In addition,
the meeting resolved to amend the Performance-based, Long-term Incentive Program
2011/2021.

For more information regarding the resolutions at the extraordinary general
meeting reference is made to the complete proposal, which is available on the
company’s webpage.

For more information, please contact:
Anders Lundström, President and CEO
Tel: +46 706 67 22 66
Email: anders.lundstrom@orexo.com

Carl-Johan Blomberg, CFO
Tel: +46 70-633 67 11
Email: carl-johan.blomberg@orexo.com

About Orexo
Orexo AB is an emerging specialty pharma company developing improved treatments
using proprietary drug delivery technology. Orexo’s expertise is within the area
of reformulation technologies and especially sublingual formulations. The
company has a portfolio of revenue-generating EU and US approved products
currently marketed under licence and a pipeline of several reformulations of
approved compounds for areas of unmet medical need. Orexo also has collaboration
projects with several international pharma companies. Orexo AB with its
headquarters in Sweden has 100 employees and is listed on NASDAQ-OMX. The
largest shareholders are Danish Novo A/S and Swedish HealthCap. More information
can be found at www.orexo.com.

Note:
This is information that Orexo AB (publ.) is required to disclose pursuant to
the Swedish Securities Markets Act. The information was provided for public
release on July 13, 2012 at 6:00 p.m. CET.